Format

Send to

Choose Destination
Eur Urol. 2014 Dec;66(6):1133-8. doi: 10.1016/j.eururo.2014.01.037. Epub 2014 Feb 9.

Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.

Author information

1
Division of Epidemiology, Departments of Medicine and Department of Surgical Urology, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: jay.fowke@vanderbilt.edu.
2
Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA; Urology Section, Veterans Affairs Medical Center, Durham, NC, USA.
3
Division of Urology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
4
Urology Section, Veterans Affairs Medical Center, Durham, NC, USA; Duke Prostate Center, Division of Urology, Department of Surgery and Pathology, Duke University School of Medicine, Durham, NC, USA.

Abstract

BACKGROUND:

Although most studies found no association between alcohol intake and prostate cancer (PCa) risk, an analysis of the Prostate Cancer Prevention Trial found that high alcohol intake significantly increased PCa risk among men randomized to the 5α-reductase inhibitor (5-ARI) finasteride.

OBJECTIVE:

Determine whether alcohol affects PCa risk among men taking the 5-ARI dutasteride.

DESIGN, SETTINGS, AND PARTICIPANTS:

Reduction by Dutasteride of Prostate Cancer Events was a 4-yr, multicenter, randomized, double-blind, placebo-controlled trial to compare PCa after dutasteride administration (0.5mg/d) with placebo. Participants had a baseline prostate-specific antigen between 2.5 and 10.0 ng/ml and a recent negative prostate biopsy. Alcohol intake was determined by baseline questionnaire, and participants underwent a prostate biopsy to determine PCa status at 2 yr and 4 yr of follow-up.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:

Multivariable logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between alcohol intake and low-grade (Gleason <7) and high-grade (Gleason >7) PCa.

RESULTS AND LIMITATIONS:

Of 6374 participants in our analysis, approximately 25% reported no alcohol consumption, 49% were moderate drinkers (one to seven drinks per week), and 26% were heavy drinkers (more than seven drinks per week). Alcohol intake was not associated with low- or high-grade PCa in the placebo arm and was not associated with low-grade PCa among men taking dutasteride. In contrast, men randomized to dutasteride and reporting more than seven drinks per week were 86% more likely to be diagnosed with high-grade PCa (p=0.01). Among alcohol abstainers, dutasteride was associated with significantly reduced risk of high-grade PCa (OR: 0.59; 95% CI, 0.38-0.90), but dutasteride was no longer associated with reduced high-grade PCa among men reporting high alcohol intake (OR: 0.99; 95% CI, 0.67-1.45).

CONCLUSIONS:

Alcohol consumption negated a protective association between dutasteride and high-grade PCa.

PATIENT SUMMARY:

We confirmed a prior study that alcohol affects PCa prevention in patients taking 5-ARIs. Patients taking 5-ARIs may wish to eliminate alcohol intake if they are concerned about PCa.

KEYWORDS:

Alcohol trial; Dutasteride; Prostate cancer

PMID:
24568894
PMCID:
PMC4127165
DOI:
10.1016/j.eururo.2014.01.037
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center